Lake Street Advisors Group LLC Purchases 234 Shares of Agilent Technologies, Inc. (NYSE:A)

Lake Street Advisors Group LLC increased its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,529 shares of the medical research company’s stock after acquiring an additional 234 shares during the period. Lake Street Advisors Group LLC’s holdings in Agilent Technologies were worth $475,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. IFP Advisors Inc boosted its stake in Agilent Technologies by 17.7% in the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter. Brown Brothers Harriman & Co. lifted its position in Agilent Technologies by 13.5% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after buying an additional 77 shares in the last quarter. Rothschild Investment LLC grew its holdings in Agilent Technologies by 19.2% during the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after acquiring an additional 79 shares during the last quarter. Rovin Capital UT ADV increased its position in Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after acquiring an additional 81 shares in the last quarter. Finally, Integrated Advisors Network LLC raised its stake in shares of Agilent Technologies by 2.5% in the third quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock worth $532,000 after acquiring an additional 86 shares during the last quarter.

Analyst Ratings Changes

Several analysts have recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Bank of America decreased their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Wells Fargo & Company dropped their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research report on Monday, December 9th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Finally, Barclays raised Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $146.15.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Agilent Technologies Stock Down 5.5 %

Agilent Technologies stock opened at $127.07 on Friday. The firm has a market capitalization of $36.25 billion, a price-to-earnings ratio of 28.75, a PEG ratio of 3.63 and a beta of 1.07. The company’s 50 day simple moving average is $140.78 and its 200 day simple moving average is $139.20. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a fifty-two week low of $124.16 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. As a group, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.78%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.